Topics

Esketamine nasal spray reduces depressive symptoms in two phase 3 studies

04:25 EDT 10 Sep 2019 | Pharmaceutical Business Review

The ASPIRE I and II trials evaluated the efficacy and safety of esketamine nasal spray in 465 patients with the moderate-to-severe major depressive disorder who have active suicidal

The post Esketamine nasal spray reduces depressive symptoms in two phase 3 studies appeared first on Pharmaceutical Business review.

Original Article: Esketamine nasal spray reduces depressive symptoms in two phase 3 studies

NEXT ARTICLE

More From BioPortfolio on "Esketamine nasal spray reduces depressive symptoms in two phase 3 studies"

Quick Search